1 / 16

HCV Protease Inhibitors in Clinical Practice

HCV Protease Inhibitors in Clinical Practice. Currently Approved HCV Agents: Telaprevir and Boceprevir. Patient Selection for HCV Triple Therapy. Telaprevir: Recommended Treatment Duration (Weeks). Telaprevir + PEG-IFN- α -2a + RBV for HCV Genotype 1.

bell-lane
Download Presentation

HCV Protease Inhibitors in Clinical Practice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HCV Protease Inhibitors in Clinical Practice

  2. Currently Approved HCV Agents: Telaprevir and Boceprevir

  3. Patient Selection for HCV Triple Therapy

  4. Telaprevir: Recommended Treatment Duration (Weeks)

  5. Telaprevir + PEG-IFN-α-2a + RBV for HCV Genotype 1

  6. Boceprevir: Recommended Treatment Duration (Weeks)

  7. Boceprevir + PEG-IFN-α-2b + RBV for HCV Genotype 1

  8. Select Predictors of SVR in Chronic HCV Genotype 1 Therapy

  9. Selected Adverse Events

  10. HCV Treatment-related Anemia

  11. Preparing Patients for HCV Treatment

  12. Abbreviations

  13. Abbreviations (cont)

  14. References

  15. References (cont)

  16. References (cont)

More Related